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Abstract
We describe a hitherto unknown feature for 27 small drug-like molecules, namely functional inhibition of acid
sphingomyelinase (ASM). These entities named FIASMAs (Functional Inhibitors of Acid SphingoMyelinAse), therefore, can be
potentially used to treat diseases associated with enhanced activity of ASM, such as Alzheimer’s disease, major depression,
radiation- and chemotherapy-induced apoptosis and endotoxic shock syndrome. Residual activity of ASM measured in the
presence of 10 mM drug concentration shows a bimodal distribution; thus the tested drugs can be classified into two groups
with lower and higher inhibitory activity. All FIASMAs share distinct physicochemical properties in showing lipophilic and
weakly basic properties. Hierarchical clustering of Tanimoto coefficients revealed that FIASMAs occur among drugs of
various chemical scaffolds. Moreover, FIASMAs more frequently violate Lipinski’s Rule-of-Five than compounds without
effect on ASM. Inhibition of ASM appears to be associated with good permeability across the blood-brain barrier. In the
present investigation, we developed a novel structure-property-activity relationship by using a random forest-based binary
classification learner. Virtual screening revealed that only six out of 768 (0.78%) compounds of natural products functionally
inhibit ASM, whereas this inhibitory activity occurs in 135 out of 2028 (6.66%) drugs licensed for medical use in humans.
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Introduction
Acid sphingomyelinase (ASM, EC 3.1.4.12) is a lysosomal
glycoprotein that catalyses the hydrolysis of sphingomyelin into
ceramide and phosphorylcholine. Fusion of secretory lysosomes
with the cell surface and translocation of lysosomal ASM onto the
outer leaflet of the cell membrane plays an important role during
stress response [1]. CD95 ligands and cytokines such as tumor
necrosis factor-a, interleukin-1 and interferon-c but also other
stimuli including oxidative stress, reactive oxygen and nitrogen
species, ionizing radiation, UV-C radiation, heat shock and other
agents of stress, injury or infections by HIV or bacteria have been
shown to stimulate ceramide production [2–7], assumed to be in
part due to increased ASM activity. Ceramide, in turn, leads to
membrane reorganization and downstream signalling that results
in cell activation, very often cell stress or apoptosis. In addition to
ASM, at least three other sphingomyelinases have been described
in mammalian cells that vary in their pH optimum and cofactor
dependency. Although these enzymes and an existing de novo
synthesis pathway are alternative mechanisms for ceramide
generation, activation of ASM itself has been proven to be critical
for some cellular responses, such as apoptosis induced by reactive
oxygen and nitrogen species [3], chemotherapy drugs such as
cisplatin [8], bacteria [5], radiation [9] and CD95 [10].
Furthermore, in contrast to other sphingomyelinases, ASM
activity is tightly regulated [11].
Ceramide is further metabolized to sphingosine and sphingo-
sine-1-phosphate by acid ceramidase (AC, EC 3.5.1.23) and
sphingosine kinases. While the biological function of sphingosine is
largely unknown, sphingosine-1-phosphate has been shown to be
involved in cellular differentiation, proliferation and cell migration
[12–16]. This dynamic balance between ceramide and sphingo-
sine-1-phosphate is referred to as the ‘‘ceramide/sphingosine-1-
phosphate rheostat’’ [17–19], maintaining the balance between
growth and cell death.
ASM is best known for its involvement in Niemann-Pick disease,
a lysosomal storage disease due to an inherited enzyme deficiency
[20]. Pathological reduction of ASM activity may be caused by
mutations in the ASM gene itself. The severity of Niemann-Pick
disease correlates with the decrease of ASM activity [21].
However, studies using cells derived from Niemann-Pick disease
patients or from ASM knock-out mice revealed that the deficiency
of this enzyme might also have beneficial consequences, including
anti-apoptotic and cytoprotective effcts. In fact, there is increasing
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evidence that ASM activation and ceramide accumulation play a
central role in the development of common human diseases
(reviewed in Smith & Schuchman [22]). Reports have been
published of aberrant activation of ASM and/or altered levels of
ceramide, for instance, for several psychiatric and neurological
disorders such as major depression [23–25], morphine antinoci-
ceptive tolerance [26], Alzheimer’s disease [27–29], spinal cord
injury [30] and seizure disorder [31].
Therefore, ASM inhibitors hold promise for a number of new
clinical therapies and might be used to prevent apoptosis and other
negative effects occurring in different disease states such as in
ischemia, stroke, Alzheimer’s dementia, Parkinson’s disease,
Huntington’s chorea, and of certain infections, in endotoxemia,
and in atherosclerosis, and for the therapy of major depressive
disorder [23,32–39]. Currently, only few examples of inhibitors
directly interacting with ASM are known. These substances
include physiological inhibitors of ASM such as phosphatidyl-myo-
inositol-3,4,5-trisphosphate [40], L-a-phosphatidyl-D-myo-inositol-
3,5-bisphosphate [41] and non-natural direct inhibitors of ASM,
such as SMA-7 [42] and AD2765 [43]. A high throughput
screening for direct ASM inhibitors was unsuccessful in finding
lead structures [44]. The rational development of compounds that
block ASM by direct interaction with the enzyme is difficult, since
the crystal structure of the enzyme is not yet available. On the
other hand, it has been known since the 1970s that some weak
organic bases have the potential to reduce the activity of ASM
[23,45–47]. It has been suggested that ASM is bound to intra-
lysosomal membranes, and thereby protected against its own
proteolytic inactivation. Weak bases, such as desipramine 168 (for
numbering of compounds see Table S1), strongly accumulate in
acidic intracellular compartments like lysosomes [48,49], a
phenomenon called ‘acid trapping’ and in the case of lysosomes
‘lysosomotropism’. This accumulation of desipramine 168 results
in detachment of the ASM from the inner lysosomal membrane
[50] and its subsequent inactivation, probably by proteolytic
degradation [51]. Weak bases, therefore, do not directly inhibit
ASM, but result in a functional inhibition of ASM. We have thus
proposed the acronym FIASMA for Functional Inhibitor of Acid
SphingoMyelinAse [39]. According to this model, functional
inhibition of ASM requires high lysosomal concentrations of a
weak basic drug.
Previously, we have shown that functional inhibition of ASM is
related to high pKa- and high logP-values and have characterized
several new FIASMAs, including the antidepressant drugs
doxepine 63, fluoxetine 104, maprotilin 109, nortriptyline 114,
paroxetine 118 and sertraline 124 [52]. The aims of the present
study were (1) to identify more FIASMAs, (2) to further improve
the in silico prediction of functional ASM inhibition by developing
compact and easily-interpretable models with high internal
consistency, (3) to investigate the relationship between permeation
of the blood-brain barrier and functional inhibition of ASM and
(4) to study the distribution of FIASMAs across different classes of
drugs licensed for medical use in humans.
Using the present knowledge about lysosomal accumulation and
drug-membrane interaction as prerequisite to functional inhibition
of ASM, we developed the following hypotheses: FIASMAs (1)
have shared structural and physicochemical properties allowing
high lysosomal drug concentrations, compatible with partitioning
into the inner surface of the lysosomal membrane and alteration of
electrostatic membrane properties. We hypothesize that FIASMAs
(2) will be found in different therapeutic drug classes and (3) belong
to diverse structural drug classes. To reach the lysosome, functional
inhibition of ASM requires penetration of drugs through biological
membranes, comparable to substances crossing the blood-brain
barrier (BBB). We therefore hypothesize (4) that FIASMAs also
penetrate the BBB and (5) are therefore overrepresented in drugs
active in the central nervous system (CNS).
Results and Discussion
Identification of novel FIASMAs
We have previously reported functional inhibition of ASM in
cell culture for a wide range of compounds at a concentration of
10 mM for 30 min incubation time [52], based on initial
experiments with fluoxetine 104. Using a cell-based simulation
model, we have meanwhile realized that very high logP- or pKa-
values or the presence of two basic nitrogen atoms leads to slow
accumulation kinetics [49]. Therefore, we have also tested longer
incubation times for such compounds (Table S1) and found lower
residual activities of ASM than previously reported for alverine 40,
astemizole 43, bepridile 46, camylofine 50, cloperastine 56,
dicyclomine 98, drofenine 64, mebeverine 110, mibefradile 74,
pimozide 81 and thioridazine 32 (see Table S1). Several of these
substances that were measured [52] as not functionally inhibiting
ASM (residual activity of ASM above 50% of control value) are
actually FIASMAs when prolonged incubation times are used
(alverine 40, dicyclomine 98, mebeverine 110, mibefradile 74,
pimozide 81). Our results demonstrate that it is important to
consider slow lysosomal accumulation kinetics in compounds with
very high pKa- and/or very high logP-values and in compounds
with two basic nitrogen atoms. In addition to identifying five more
of the previously-tested 101 compounds [52] as FIASMAs taking
their slower lysosomal accumulation into account (see Table S1:
alverine 40, dicyclomine 98, mebeverine 110, mibefradile 74,
pimozide 81), we have identified 22 other previously unknown
FIASMAs out of our new set of 175 small drug-like compounds
(residual activity of ASM of #50%: aprindine 141, biperidene
149, carvedilol 160, cepharantine 161, clemastine 170, clofazi-
mine 172, conessine 175, desloratadine 182, dimebon 189,
emetine 196, flupenthixol 208, fluphenazine 209, fluvoxamine
210, hydroxyzin 219, loperamide 227, mebhydroline 229,
perphenazine 249, profenamine 258, sertindole 277, solasodine
278, tomatidine 291, zolantidine 276). Four of them (dimebon
189: residual ASM activity 44.1%; fluvoxamine 192: residual
ASM activity 37.4%; hydroxyzin 219: residual ASM activity
43.0%; mebhydroline 207: residual ASM activity 41.9%) were
classified as FIASMAs albeit with less reliability due to
experimental error. To the best of our knowledge, functional
inhibition of ASM has not previously been described for any of the
compounds presented here. Looking at the whole group of
FIASMAs which we experimentally investigated (n= 72, Kornhu-
ber et al. 2008 [52] and Table 1), we noticed some general
characteristics. These compounds had moderate to high logP-
values (ACD10; mean 6 SD: 5.4561.13; range: 2.03–8.89) and
possessed at least one basic nitrogen atom responsible for
moderate to high pKa-values (ACD10; mean 6 SD: 9.0461.18;
range: 4.81–11.20). This qualifies all FIASMAs as cationic
amphiphilic drugs. Most FIASMAs had a molecular weight below
500 (ACD10; mean 6 SD: 366.3685.1; range: 263.4–645.3).
Functional inhibition of ASM is bimodally distributed
Analysis of the whole set of compounds (n = 276), reveals a
bimodal distribution of drugs with respect to functional inhibition
of ASM (Figure 1) and a significant deviation from the normal
distribution (Kolmogoroff-Smirnov: p,0.001), with the lowest
occurrence of FIASMAs at a residual activity between 50 and
60%. Both subpeaks of the bimodal distribution did not
significantly deviate from a normal distribution. The reason for
Novel FIASMAs
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the bimodal distribution may be the inevitable presence of
physicochemical properties that are non-linearly related to
lysosomal drug accumulation and that work in a synergistic way.
Since our experimentally-tested compounds were not randomly
chosen, a selection bias might also contribute to the bimodal
distribution.
Random forest learners provide a good binary prediction
of functional inhibition of ASM
We divided the dataset into two groups – active compounds
(#50% residual ASM activity, class 1, n = 72) and inactive
compounds (.50% residual ASM activity, class 0, n= 204).
Usually, dichotomizing continuous variables results in a number of
statistical problems, including a loss of statistical power to detect a
relation between a variable and outcome [53–55]. In our data,
dichotomization is justified by the pronounced bimodal distribu-
tion. We performed a qualitative prediction of functional inhibition of
ASM using the whole set and random forest learners. The
prediction accuracy in the set increased with the number of
attributes used. A high precision of prediction was reached with
n= 4 attributes, which is only marginally improved by adding a
fifth descriptor (Table 2). The successful 4-descriptor combination
included logPACD10_logWeight, pKa1_plus_pKa2ACD10mod,
pKaMA_ACD10 and si_Weight_vsa_pol. These four descriptors
were only moderately correlated to each other (Spearman rank
correlation r2 between 20.598 and 0.314, n= 276) and thus
provide complementary information. The descriptors logP and
pKa have been discussed most frequently in the context of
lysosomal accumulation [48,49]. Intermediate to high logP values
have previously been identified as an important precondition for
lysosomal accumulation. However, logPACD10_logWeight
( = logPACD102K logMW) is more closely related to the
diffusion of small molecules through lipid phases than logP itself
and has been used to predict BBB permeation [56,57]. The
descriptor pKa1_plus_pKa2ACD10mod represents the sum of the
pKa-values of the most basic and the second-most basic nitrogen
atoms and thus takes into account the impact of a second basic
functional group. The descriptor pKaMA_ACD10 represents the
pKa-value of the most acidic group and thus guarantees that acids
are correctly classified as being inactive. vsa_pol is an approxi-
mation to the sum of van-der-Waals surface areas of polar atoms
and has been described to predict BBB permeability [58]. For this
descriptor, both hydrogen bond donors and acceptors count as
polar atoms. The size-intensive form of the descriptor was chosen
here. The four molecular descriptors thus represent electrostatic
(pKa1_plus_pKa2ACD10mod, pKaMA_ACD10), hydrophobic
(logPACD10_logWeight), polar (vsa_pol) and steric (weight)
properties of the molecules. No further steric descriptors were
chosen into the model. The reason for this is probably the low
variance of steric descriptors as all of the compounds investigated
here are small drug-like molecules. The 4-descriptor model
presented here is simple, easy to interpret, has high internal
consistency and is meaningful in the context of lysosomal
accumulation (Table 2). None of the 276 compounds was
incorrectly predicted by the 4-descriptor model.
Based on a smaller set of experimentally investigated com-
pounds (n = 101) and a decision tree learner we had previously
suggested a 3-descriptor model (logPACD10, pKa1ACD10, k) for
qualitative prediction of functional inhibition of ASM [52].
Applying this 3-descriptor model on the large experimental
dataset available in the present study (n= 276) still results in a
reasonable good prediction of functional inhibition of ASM (mean
bootstrap-validated Youden-index: 0.57560.085, mean bootstrap-
validated accuracy 0.83160.033, Youden-index without boot-
strap-validation 1.0, accuracy without bootstrap-validation 1.0).
However, the descriptor-combinations presented here (Table 2)
outperform the previous prediction system. The previously
suggested model [52] was now improved in several ways by using
advanced molecular descriptors (e.g. logPACD102K logMW
instead of logPACD10; pKa1ACD10+pKa2ACD10 instead of
pKa1ACD10), by using four instead of three molecular descrip-
tors, by using a random forest learner instead of a simple decision
tree learner and by using rigorous model validation. This led to a
much more precise prediction system.
Whenever a structure-property-activity relationship (SPAR)
model is built, there is a probability that the best model is chance
correlation. We therefore performed a response permutation test
(also known as Y-scrambling [59–61]). If a strong correlation
remains between the selected descriptors and the randomly
permutated response, the significance of the proposed model is
suspect. The 4-descriptor model (logPACD10_logWeight, pKa1_
plus_pKa2ACD10mod, pKaMA_ACD10, si_Weight_vsa_pol)
was recalculated for a randomly reordered response. This
procedure was performed 1000 times using different random
seeds for permutation, resulting in a mean bootstrapping validated
Youden-index of 0.00160.034 and a mean bootstrapping
Table 1. Newly-identified FIASMAs.
Generic name or
substance code CID ATC code FDA status [70]
Alverine 40 3678 A03AX08 Not listed
Mibefradile 74 60663 C08CX01 Not listed
Pimozide 81 16362 N05AG02 Prescription drug
Dicyclomine 98 3042 A03AA07 Prescription drug
Mebeverine 110 4031 A03AA04 Not listed
Aprindine 141 2218 C01BB04 Not listed
Biperidene 149 2381 N04AA02 Prescription drug
Carvedilol 160 2585 C07AG02 Prescription drug
Cepharantine 161 360849 Not listed Not listed
Clemastine 170 26987 D04AA14 Prescription drug
Clofazimine 172 2794 J04BA01 Prescription drug
Conessine 175 441082 Not listed Not listed
Desloratadine 182 124087 R06AX27 Prescription drug
Dimebon 189 197033 Not listed Not listed
Emetine 196 10219 P01AX02 Not listed
Flupenthixol 208 5281881 N05AF01 Not listed
Fluphenazine 209 3372 N05AB02 Prescription drug
Fluvoxamine 210 5324346 N06AB08 Prescription drug
Hydroxyzin 219 3658 N05BB01 Prescription drug
Loperamide 227 3955 A07DA03 Prescription drug
Mebhydroline 229 22530 R06AX15 Not listed
Perphenazine 249 4748 N05AB03 Prescription drug
Profenamine 258 3290 N04AA05 Discontinued drug
Sertindole 277 60149 N05AE03 Not listed
Solasodine 278 442985 Not listed Not listed
Tomatidine 291 65576 Not listed Not listed
Zolantidine 306 91769 Not listed Not listed
See Table S1 for further details and numbering of compounds.
CID = PubChem Compound ID.
doi:10.1371/journal.pone.0023852.t001
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validated accuracy of 0.67560.014 for the whole experimental set
(n = 276). The performance of the 4-descriptor model applied to
the original dataset is therefore more than 15 standard deviations
above random (mean accuracy in the whole experimental
set = 0.884) indicating a large distance between a random response
model and a true response model. The whole set comprised 276
compounds, 204 of them in class 0 (inactive) and 72 in class 1
(active). A model assuming all compounds would belong to class 0
(zero rule model) would have an accuracy of 0.739. The accuracy
of the chosen model applied to the original dataset is significantly
higher than the zero rule model, whereas the model applied to
randomly reordered response values has a performance which is
even lower than the zero rule model.
The whole process from data pre-processing to model
generation and interpretation was in accordance with the
OECD/IOMC guidelines for quantitative structure-activity rela-
tionship development [62]. This means that our study had (1) a
defined endpoint, (2) an unambiguous algorithm, (3) a defined
domain of applicability, (4) appropriate measures of goodness-of-
fit, robustness and predictivity and (5) a mechanistic interpretation.
Additive effect of FIASMAs
Co-application of structurally diverse FIASMAs results in an
additive functional inhibition of ASM, suggesting that these
compounds share the same mechanism of inhibition. This is
exemplified here by the additive effect of amitriptyline 6 and
fluoxetine 104 (Figure 2).
FIASMAs tend to cross the blood-brain barrier
The blood-brain barrier (BBB) is a selective barrier formed by
the endothelial cells that line cerebral microvessels [63]. Tight
junctions between adjacent endothelial cells force most molecular
Figure 1. Analyzed compounds show a bimodal distribution with respect to functional inhibition of ASM. The histogram includes
results of 276 experimentally investigated compounds (see Table S1). The line represents a Gaussian fit to the two peaks.
doi:10.1371/journal.pone.0023852.g001
Table 2. Descriptor combinations were selected by a 200-fold bootstrap-validated Youden-index based on a binary random forest
learner using the whole experimental set.
Mean 200fold bootstrap-validation Final model without validation
n Descriptors
Youden-index
Mean ± SD
Accuracy
Mean ± SD Youden-index Accuracy
1 logPACD10_logWeight 0.29460.107 0.73660.038 0.850 0.949
2 logPACD10_logWeight, pKa1_plus_pKa2ACD10mod 0.56760.090 0.82960.031 0.967 0.989
3 logPACD10_logWeight, pKa1_plus_pKa2ACD10mod,
pKaMA_ACD10
0.62660.087 0.85260.031 0.990 0.993
4 logPACD10_logWeight, pKa1_plus_pKa2ACD10mod,
pKaMA_ACD10, si_Weight_vsa_pol
0.680±0.087 0.884±0.030 1.000 1.000
5 logPACD10_logWeight, pKa1_plus_pKa2ACD10mod,
pKaMA_ACD10, si_Weight_vsa_pol, si_Weight_prot_n_PI
0.71460.086 0.89760.027 1.000 1.000
A 4-descriptor combination provided high internal consistency, which is only marginally improved by addition of a fifth descriptor. Bootstrap-validated performance
measures are given as mean 6 SD values.
doi:10.1371/journal.pone.0023852.t002
Novel FIASMAs
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traffic across the BBB to take the transcellular route [64]. Small
lipophilic agents can diffuse freely through the lipid membranes.
Most CNS-active drugs use this transcellular lipophilic pathway.
Compounds entering the brain have to cross two membrane
barriers (both luminal and abluminal plasma membrane) and the
cytoplasm of the endothelial cells in brain capillaries. FIASMAs
have to go a similar way through the cell to reach the lysosome:
they cross two membrane barriers (plasma membrane of the cell,
lysosomal membrane) and the cytoplasm. Therefore an analogy
between the BBB and the blood-lysosomal barrier can be assumed.
For 64 of the 276 compounds investigated here, we found
experimental logBB values (logarithmic ratio between the
concentration of a compound in brain and blood) in the literature.
When residual ASM activity is plotted against logBB values
(Figure 3), it is apparent that functional inhibition of ASM
(residual activity #50%) is found only for compounds that
efficiently cross the BBB (logBB$0).
FIASMAs violate Lipinski’s Rule-of-Five more often than
compounds without effect on ASM
We investigated whether or not our experimentally tested
compounds (n = 276, Table S1) are in agreement with Lipinski’s
Rule-of-Five [65]. While 59 of 204 (28.9%) of compounds lacking
a significant effect on ASM activity violated the Lipinski’s Rule-of-
Five, violation occurred in 37 of 72 (51.4%) of FIASMAs (chi-
square test, p = 0.001, Table 3). In most of the FIASMAs violation
of the Rule-of-Five was due to high lipophilicity. Nevertheless,
FIASMAs are orally active and most of them are probably also
CNS-active drugs.
Virtual screening shows that FIASMAs are enriched in
groups of drugs acting at excitable cells but are rare
among natural products
Most of the clinically approved compounds have been
developed without specific goals regarding logP- and pKa-values.
Therefore, there should be no remarkable differences in these
physicochemical properties between groups of drugs approved for
medical use. To get a complete picture of the distribution of
functional inhibition of ASM within approved drugs, we used the
Anatomical Therapeutic Chemical (ATC) drug classification
system recommended by the World Health Organization
(WHO). Based on the random forest model described above, we
analyzed a total of 2440 compounds distributed across 86 third-
level drug groups of the ATC codes (with several substances
occurring more than once; 2028 different compounds) by a virtual
screening approach and found physicochemical characteristics
indicative of functional inhibition of ASM in 157 of the 2440
ATC-listed compounds (6.43%). Since some of the drugs in the
ATC system are chemically identical, but have a unique ATC-
code because of their different clinical indications, a total of 135 of
2028 unique compounds (6.66%) was predicted to functionally
inhibit ASM. The distribution of the 157 functional ASM
inhibitors across the 86 pharmacologically relevant therapeutic
groups significantly deviated from the expected values (Fisher’s
exact test, p,0.001), but clustered clearly in a few groups. The
multiple test correction on Fisher p-values revealed a significant
overrepresentation of FIASMAs in only a few therapeutic groups,
namely A03 (drugs for functional gastrointestinal disorders), A15
(appetite stimulants), C08 (calcium channel blockers), D04
(antipruritics), N04 (anti-parkinson drugs), N05 (psycholeptics),
N06 (psychoanaleptics) and R06 (antihistamines for systemic use).
Since group size of the ATC second level drug groups varies
strongly, the p-value has a limited explanatory power. From a
biological point of view, groups with a high fraction of FIASMAs
may be still of interest, even if the p-value is not significant owing
to the small size of the group, such as A04 (antiemetics and
antinauseants). One common feature of these ATC subgroups
with a significant overrepresentation of FIASMAs is the pharma-
codynamic involvement of excitable cells where many FIASMAs
appear to act primarily. Furthermore, it is evident, that several of
the second-level ATC subgroups with a significant number of
FIASMAs belong to the CNS active groups (N04, N05, N06).
In contrast to approved drugs for medical use, we found by
virtual screening that FIASMAs are rare in natural products. The
molecular descriptors necessary for application of the model were
calculable in 787 of the 800 ‘‘Pure Natural Products’’ [66]. Two
compounds with quaternary nitrogen atoms were excluded. Then
we removed 17 duplicates. In six of the remaining 768 compounds
(0.78%) the model indicated functional inhibition of ASM. Five of
these predicted compounds were also part of the experimental set
(Table S1): cepharanthine 161, conessine 175, emetine 196,
solasodine 278 and tomatidine 291 and did indeed show
functional inhibition of ASM. The rate of predicted FIASMAs
in natural products is much lower than the rate of predicted
FIASMAs observed in drugs licensed for medical use in humans
(6.66%). The applicability domain of our prediction model is small
drug-like molecules. The set of Pure Natural Products differs in
chemical space from the small drug-like molecules, meaning that
these results have to be interpreted with caution.
FIASMAs are structurally heterogeneous
Chemical space and structural diversity are important when
comparing different sets of compounds. It is not valid to extend
results obtained in one set of compounds to other compound
collections without taking into account structural diversity. In
order to compare the degree of structural diversity between sets of
compounds, we have developed a new and simple measure termed
‘‘relative structural diversity’’ (divrel). This simple measure uses a
hierarchical clustering of Tanimoto-coefficients [67] based on 2D-
fingerprints (see experimental section) and may be used in addition
to more complicated indicators of structural diversity [68]. The
divrel of the FIASMAs (n = 72, divrel=0.667) is somewhat lower but
Figure 2. FIASMAs work in an additive way: The combination
of a subthreshold-concentration of amitriptyline 6 and fluox-
etine 104 (2.5 mM) results in functional inhibition of ASM. This
effect is also evident at higher concentrations. Mean values6 SD from 3
experiments are given.
doi:10.1371/journal.pone.0023852.g002
Novel FIASMAs
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still high compared to the divrel of the whole experimental set
(n = 276, divrel=0.711). For comparison, divrel is similar in the set
of ATC compounds investigated (n = 2028, divrel=0.709) as well
as in the set of natural products (n = 768, divrel=0.747) (Table 4).
Thus, the molecular structure of FIASMAs varies widely, as
indicated by the high number of clusters. This is supported by the
fact that FIASMAs represent different therapeutic classes and
different structural classes as evidenced by their ATC-codes (see
Table 1). Our results prove that functional inhibition of ASM does
not depend on a specific molecular drug class. Instead of specific
structural prerequisites, functional inhibition of ASM requires
specific physicochemical characteristics of compounds, resulting in
high intra-lysosomal concentrations and partitioning of the drug
into the inner leaf of the lysosomal membrane.
In the current study we used several different compound
collections. The experimental set investigated here is showing
comparable divrel values to the ATC set. It is therefore appropriate
to apply conclusions from the experimental set onto the larger
ATC collection. The set of 72 FIASMAs is a subset of the
experimental set, which in turn is largely a subset of the ATC drug
library. Therefore, these three sets occupy a comparable region of
the chemical space, as all these sets are mainly composed of small
drug like molecules. The Pure Natural Products cannot easily be
compared to the drug-like molecules as their chemicals space
differs.
Clinical implications of the findings presented here
Most of the newly defined FIASMAs described here are
included in the WHO drug list of approved and essential
medicines [69] and about half of them appear in the US Food
and Drug Administration (FDA)-approved drug list [70] (Table 1).
These substances not only possess a low toxicity but also a record
of a long-term clinical experience – some have been in use for the
last five decades. FIASMAs have a number of favourable
properties in the context of clinical application [39], suggesting
the potential for rapid advancement into preclinical and/or
clinical trials. The therapeutic consequences of functional
Figure 3. Functional inhibition of ASM appears to be associated with good passive diffusion across the blood-brain barrier.
Experimental logBB values were compiled from the literature, with values greater than 0 indicating good blood-brain barrier permeability. Functional
inhibition of ASM was experimentally determined in cell culture; residual ASM activity below 50% relative to control cells indicates active compounds.
See also results in Table S1.
doi:10.1371/journal.pone.0023852.g003
Table 3. FIASMAs frequently violate Lipinski’s Rule-of-Five.
Experimentally-determined ASM inhibitory activity
FIASMA Not acting as FIASMA
Rule-of-Five = 0 35 145
Rule-of-Five.0 37 59
Chi-square-test, p = 0.001.
Violation was assumed when there was a contradiction to any of the four rules.
Violation of Lipinski’s Rule-of-Five was calculated by ACD10 for all compounds
with experimentally-determined ASM activity (n = 276).
doi:10.1371/journal.pone.0023852.t003
Table 4. Comparison of the relative structural diversity of the
compound sets investigated here.
n divrel
FIASMAs 72 0.667
Whole experimental set 276 0.711
ATC-set 2028 0.709
Pure Natural Products 768 0.747
Structural diversity was estimated by a new measure called relative structural
diversity (divrel, see experimental section). The set of FIASMAs is a subset of the
whole experimental set investigated here.
doi:10.1371/journal.pone.0023852.t004
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inhibition of ASM are yet poorly understood, however they may
induce a number of clinically desired effects. Ceramide and its
metabolite sphingosine-1-phosphate have been shown to antago-
nistically regulate apoptosis, cellular differentiation, proliferation
and cell migration. Inhibition of ASM results in anti-apoptotic,
proliferative and anti-inflammatory effects. Furthermore, ASM
could play a key role in the pathophysiology of depression and in
the action of antidepressant drugs [23]. Inhibitors of ASM
therefore hold promise for a number of new clinical therapies.
Several examples are given here: Induction of stroke by
experimental ischemia of the brain was shown to correlate with
an activation of the ASM and a release of ceramide [71,72].
Importantly, ASM-deficient mice were protected from tissue
damage caused by focal cerebral ischemia. Furthermore, the
ethanol-induced neuronal cell death is mediated, at least in part,
by activation of ASM and generation of ceramide [73]. In
addition, the lethal gastrointestinal syndrome, which limits the
efficacy of radiation and chemotherapy, apparently results from
apoptotic damage of the endothelial cells of the microvasculature
of the small intestine. Genetic inactivation of ASM prevents this
toxicity [74]. Infection induced by the human immunodeficiency
virus type I (HIV-1) serves as a further example. HIV-1 induces a
dramatic depletion of CD4+ T cells in infected individuals, finally
leading to AIDS (acquired immunodeficiency syndrome). The
massive loss of CD4 T-lymphocytes is assumed to result from
apoptosis, probably due to enhanced sphingomyelin breakdown
and accumulation of intracellular ceramide [75]. Interestingly,
HIV-1 infected long-term nonprogressors have less elevated
lymphocyte-associated ceramide than subjects with evolving AIDS
[76], which is paralleled by a lower frequency of apoptotic CD4
and CD8 cells in long-term nonprogressors compared to patients
with AIDS [77]. The endotoxic shock syndrome, which is
characterized by systemic inflammation, multiple organ damage,
circulatory collapse and death, is caused by disseminated
endothelial apoptosis sequentially mediated by TNF and ceramide
generation [78]. Blocking of this cascade by ASM inhibitors should
be preventive and/or therapeutic against the endotoxic shock
syndrome. Finally, an imbalance between ASM and acid
ceramidase followed by ceramide accumulation has been demon-
strated in the hereditary disease cystic fibrosis [79]. In experi-
mental animals, FIASMAs normalize pulmonary ceramide and
inflammation [80]. In a clinical pilot study, amitriptyline 6 led to
an improved respiratory function in affected patients [81]. Further
examples include the treatment of e.g. Alzheimer’s disease, major
depression, inflammatory bowel disease [42], liver cell death and
anaemia occurring in Wilson disease, and pulmonary edema in
acute lung injury [82]. Recently, it has been shown that gilenya
(FTY720), a drug licensed for treatment of multiple sclerosis, acts
as a FIASMA [83]. This novel mechanism of action may explain
at least in part the beneficial effects of gilenya in multiple sclerosis.
AC is a lysosomal enzyme degrading ceramide to sphingosine.
Cationic amphiphilic agents like desipramine, chlorpromazine and
chloroquine have been shown to result in both, a reduced level of
AC protein and in an increased level of cellular ceramide [84,85].
Despite its potential importance, the influence of medically used
drugs on AC has not yet been systematically studied. In a cell
culture-based pilot study on more than 100 small drug-like
compounds (CM, unpublished), FIASMAs had a significantly
stronger AC inhibitory effect than non-FIASMAs. However, the
effect on AC was less pronounced compared to their effect on
ASM as none of the compounds reduced AC activity to levels
below 50%. Moreover, because of the considerably lower enzyme
activity of the AC compared to ASM (about 25 fold in cell lysates
using fluorescently labelled substrates; CM unpublished), the
absolute net effect of potentially inhibitory drugs is expected to be
dominated by their influence on ASM. The observation of
reduced ceramide levels in the mouse hippocampus after
application of amitriptyline or fluoxetine (EG, unpublished results)
is in agreement with this hypothesis. Nevertheless, the potential
dual effect of small drug-like compounds on ASM as well as AC
deserves further research with the aim to identify compounds with
specific inhibitory activity for therapeutic use.
Strengths and limitations of the study
Strength: We identified 27 novel FIASMAs, many of them
FDA-approved for clinical use in humans. Model construction was
based on a large number of experimentally investigated com-
pounds, and used standard Molecular Operating Environment
(MOE) descriptors as well as a multitude of novel hypothesis-
driven molecular descriptors, like k, n_pdN, CSA and calculated
lysosomal drug concentration (Table 5). We did not use 3D-
descriptors, which depend on stereoisomers, preprocessing and
energy minimization. Furthermore, we made use of size-intensive
descriptors. Remarkably, none of the descriptors of the final model
was a standard MOE-descriptor. We applied machine learning
algorithms with a low proneness to overfitting (random forest) and
performed a rigorous model validation (bootstrap). Our perfor-
mance measure was well suited for dysbalanced bimodal data
(Youden-index). We thus developed a simple model with high
internal consistency, high external predictivity (mean bootstrapped
accuracy of about 87% in the experimental set), and with a
mechanistic interpretation. Finally, we introduce a new measure
for comparison of structural heterogeneity between sets of
compounds (divrel).
Limitations: The chemoinformatic model presented here is valid
for small drug-like molecules only. The model allows the
qualitative prediction only. The effect of a substance on ASM
activity under therapeutic conditions in vivo depends on the
interplay between compound-, treatment- (such as dose and
application route) and organism-related variables. Future studies
should clarify whether or not functional inhibition of ASM occurs
at therapeutic concentrations of the drugs investigated here.
Conclusions
Functional inhibitors of ASM (FIASMAs) are an important class
of drugs with newly emerging broad clinical applications. In the
present study we have identified 27 novel FIASMAs. Based on a
large set of experimental data, we have developed a chemoinfor-
matic model for the accurate prediction of functional inhibition of
ASM. Furthermore, we describe important properties of FIAS-
MAs, such as BBB permeability.
Materials and Methods
Set of compounds
In addition to the set of 101 compounds previously experimen-
tally investigated with regard to functional inhibition of ASM [52],
we selected 175 small organic, drug-like compounds or natural
products. The selection aimed at obtaining compounds with high
structural diversity, with diversity regarding strength and number
of acidic and basic functional groups, and diversity regarding logP
values. Basic lipophilic compounds were overrepresented in order
to obtain a sufficient number of FIASMAs and in order to avoid a
greatly unbalanced class distribution for classification tasks. Of the
total set of 276 compounds (Table S1) with a mean molecular
weight of 359.9 (88.2–847.0), 23 were acids with a most acidic
pKa-value as estimated by ACD10 [86] below 10 and no relevant
basic group (‘‘acid’’) and 155 were weak bases with a most basic
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pKa-value$3 and neither another relevant basic nor any relevant
acidic group (‘‘monobase’’). Further 22 compounds possessed both
a basic nitrogen atom with a pKa-value$3 and an acidic group
with a pKa-value below 10 (‘‘zwitter’’). Additional 45 compounds
contained two basic nitrogen atoms both with pKa-values$3 and
no relevant acidic group (‘‘bibase’’). The remaining 31 compounds
either had no ionisable functional group at all (n = 9) or had pKa-
values outside the biologically relevant range (n = 22).
Structure entry
Molecular structures were obtained from the PubChem-Project
page [87,88] (Table S1).
Chemicals
Aclacinomycin-A 133, acrivastine 134, amorolfine 139,
clonidine 173, lynestrenol 228, montelukast 239 and rolipram
271 were purchased from Biotrend Chemikalien (Ko¨ln,
Germany); phenylmethylsulfonyl fluoride 253 and S-methyli-
sothiourea 274 from Calbiochem (Merck, Darmstadt, Ger-
many); allylestrenol 135, atovaquone 142, barnidipine 146,
butenafine 155, cepharanthine 161, chlorquinaldol 166,
clemastine 170, dienestrol 187, dutasteride 195, nelfinavir
243, solasodine 278 and vinblastine 299 from Chemos
(Regenstauf, Germany) and dimebon 189 from Aurora
Feinchemie (Graz, Austria). Apomorphin 140, doxorubicin
193, phenserine 251, pranlukast 257, raloxifene 266 and
zolantidine (SKB41) 306 were obtained from Tocris (Bristol,
UK) and aprindine 141, biperidene 149, buclicine 152,
buspiron 154, diosmin 190, emetine 196, encainide 197,
fosinopril 211, hydroxyzin 219, ropinirole 272, thiocarlide 287,
tiagabine 288 and zafirlukast 305 from VWR (Darmstadt,
Germany). Quetiapine 264 was a gift of AstraZeneca (Wedel,
Germany). All other substances investigated experimentally
were obtained from Sigma-Aldrich (Munich, Germany). All
compounds were used in the highest purity available.
Table 5. List of programmed and calculated descriptors that were used in addition to the standard MOE-descriptors.
Name of the descriptor Description
AA Length of the amphiphilic axis [95]
CSA Cross-sectional area [95]
NOOM Number of atoms outside the amphiphilic axis [95]
Li Longest distance from an ionized atom to another atom [95]
Mpc Longest distance from the atom with the highest partial charge [95]
n_qN Number of quaternary nitrogen atoms
n_COOH Number of carboxylic acid functions [133]
n_OpN Sum of nitrogen and oxygen atoms [134]
n_hal Number of halogen atoms (based on: Norinder and Haeberlein [134])
n_XpC Sum of halogen and carbon atoms (based on: Norinder and Haeberlein [134])
n_ion Number of ionized atoms (based on: Lanevskij et al. [56])
n_PI Number of positive ionizable groups (based on: Lanevskij et al. [56])
n_pdN Number of protonized delocalized nitrogen atoms in the N-C =N motif
n_pH Number of polar hydrogen atoms [135]
n_pol Number of polar atoms [135]
n_amines Number of amines
n_pN number of protonated nitrogen atoms at pH 7
I3 +1 for amines, 21 for acids, otherwise 0 [136]
QMAXneg Highest negative partial charge [133]
QMAXpos Highest positive partial charge [133]
QMEANN Average partial charge in nitrogen atoms
QSUMH Sum of all partial charges on hydrogen atoms
QSUMO Sum of all partial charges on oxygen atoms [133]
QMINN Lowest partial charge on nitrogen atoms
QSUMN Sum of all partial charges on nitrogen atoms
Qamines Average partial charge on amines
CLys Calculated lysosomal concentration [49]
LA Lipoaffinity [137]
logPACD10_minus_O_N LogP – number of oxygen and nitrogen atoms [134]
logPACD10_logWeight logPACD102K*logWeight [56,57]
pKa1_plus_pKa2ACD10 pKa1ACD10+pKa2ACD10
pKa1_plus_pKa2ACD10mod if pKa2ACD10.0: pKa1ACD10 + pKa2ACD10, else: pKa1ACD10
si_Weight-Descriptors Size-intensive descriptors [96] using molecular weight as divisor
doi:10.1371/journal.pone.0023852.t005
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Cell culture
Human brain neuroglioma H4-cells were purchased from
Promochem (Wesel, Germany). H4-cells were cultured as
described previously [52]. Only cells tested negative for myco-
plasma infection were used in the experiments.
Kinetics of lysosomal accumulation
Usually, 30 min of incubation of H4-cells with the test drug was
sufficient to induce functional inhibition of ASM. Due to slow
accumulaion kinetics some compounds required a longer incuba-
tion time. However, prolonged incubation with some compounds
(astemizole 43, mibefradil 74, penfluridol 79, fluoxetine 104,
sertindole 249, thioridazine 32) resulted in cell death. We
therefore aimed at a minimal but still sufficient incubation time
for all compounds, which was estimated using a previously
developed numerical single cell model [49]: Accumulation of
molecules in the cell by diffusion from the external solution into
the cytosol, lysosome and mitochondria was calculated with the
Fick-Nernst-Planck-equation. The cell model considers the
diffusion of neutral and ionic molecules across biological
membranes, dissociation into mono- or bivalent ions, adsorption
to lipids, and electrical attraction or repulsion. We used the
parameters of the standard model [49] as well as the logP-, most
basic and most acidic pKa-values as calculated by ACD10 [86]
(Table S1). Four different models (‘‘monoacid’’, ‘‘monobase’’,
‘‘bibase’’ and ‘‘zwitter’’) implemented in Excel sheets were used for
kinetic calculations (model version: July 2009). There was no
amphoteric compound in our dataset. In the absence of pKa-
values in the relevant regions, the monoacid model was used with
a pKa-value of 15.
Experimental determination of ASM activity
The activity of ASM was determined in whole cell lysates, as
previously described [89]. We aimed to develop a qualitative
(binary) SPAR model. Therefore, we did not determine IC50
values, but we determined whether or not a compound acts as
functional inhibitor of ASM. Thus, we used a single high
concentration of a compound and a sufficient incubation time,
which depends on the pharmacokinetic properties of the
compound. After the substance was added to the growth medium
at a final concentration of 10 mM, cells were kept at 37uC in a
humidified atmosphere at 8.5% CO2 for 30 minutes (DMEM:
pH 7.5). Compounds with predicted slow lysosomal accumulation
kinetics [49] were also investigated at longer incubation times
(Table S1). Results are given as residual ASM activity (%)
normalized to control cells treated with the solvent alone and
represent mean values of three independent experiments, each
with a standard deviation of approx. 16%. Because of the bimodal
distribution of functional inhibition of ASM (see below), a residual
ASM activity #50.0% in H4-cells was rated as positive.
Statistical analysis
Deviation from normal distribution (two-sided Kolmogoroff-
Smirnov) and chi-square statistics were computed using PASW
(Version 18, Chicago, Illinois). One-sided Fisher’s exact probabil-
ity test with Benjamini-Hochberg [90] correction for multiple
testing was computed using R software (version version 2.7.0) [91].
Computation of molecular descriptors
Molecular descriptors were calculated by the ACD/LogD Suite,
version 10 [86] (the two most basic pKa-values, the most acidic
pKa-value, logP-value), by visual inspection of the molecules
[number of heavy atoms at the most basic nitrogen atom (k [52])]
and by MOE 2009.10 [92]. The lysosomal concentration of each
drug was calculated by a previously developed numerical single
cell model [49] (see above) and was also used as a molecular
descriptor (CLys). It has previously been suggested that the lowest
cross-sectional area of a molecule perpendicular to the amphiphilic
axis determines the insertion of a molecule into a biomembrane
and thereby its passive diffusion across the BBB [93,94]. The
lowest cross-sectional area (CSA, Table 5) of the molecules
perpendicular to the amphiphilic axis in the membrane bound
conformation and related molecular descriptors were calculated as
previously described [95]. A simple division of molecular
descriptors by chemical sample size creates size-intensive descrip-
tors which were shown to result in more compact and more stable
models [96]. We used molecular weight (MW) to calculate a size-
intensive form of every molecular descriptor. Furthermore, we
used an MW-based correction of logP-values (logP2K*logWeight
[56,57]). Further information on these descriptors is available in
Table 5 and in the literature [59,97].
Data pre-processing
Data pre-processing was performed using RapidMiner 5.1 [98].
Features with very low variance were eliminated. Missing values
for the most basic pKa-values were substituted by 0, missing most
acidic pKa-values were substituted by 15, missing values for k were
substituted by 12. Otherwise, we used only molecular descriptors
that were available for all compounds and thereby obtained a total
of 708 molecular descriptors. The presence of irrelevant and
redundant attributes may reduce the performance of learners such
as decision tree and random forest [99]. Therefore, before
applying random forest learners we reduced the dimensionality
of the data by applying feature selection methods. We used both a
hypothesis-driven and a hypothesis-free feature selection approach
[100,101] to select descriptors with potential relevance. For the
hypothesis-free selection, attributes were chosen by at least one of
the following methods: wrapper [102], relief [103,104], correlation
based weighting, information gain weighting, standard deviation
based weighting, support vector machine based weighting and rule
based weighting. We thus ended up with about 100 molecular
descriptors used for random forest learners.
Model construction
Models were generated using machine learning algorithms
[105,106] provided by RapidMiner 5.1 [98]. The whole
experimental set was used, since examples are too precious to
waste during model generation [107]. A modified beam-search
[108] served to identify high-performing single attributes or
attribute combinations. Models were validated by bootstrapping
(n= 200). Because of the unbalanced class distribution, the
Youden-Index [109–111] (sensitivity + specificity21) was chosen
as primary performance measure evaluating models based on two-
class learners. We used a random forest learner [112] for binary
classification. In contrast to a simple decision tree learner, random
forest learners are more resistant against overfitting and result in
more stable models, meaning that small changes in the training set
do not lead to completely different models [113,114], and lead to
better predictivity on unknown compounds. The parameters used
were: ntree = 51 (number of trees to build), nodesize = 1 (size of the
terminal node of the trees in a random forest), mtry = log(m)+1
(number of attributes randomly selected at each node, where
m=number of attributes available), allowed maximal depth of the
trees = 8.
Whenever a structure activity relations (SAR) model is built,
there is a probability that the best model is chance correlation. We
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used the response permutation test, also known as Y-scrambling
[59–61,115] to detect random effects.
Relative structural diversity of the set of compounds
used
In order to estimate the structural diversity of our investigated
sets of compounds, we performed a hierarchical clustering based
on Tanimoto coefficients [67] for fingerprints based on tagged
graph triangles (TGT) [116,117]. We calculated the number of
clusters at 0.85 similarity measured by Tanimoto coefficients and
divided it by the total number of compounds in the test set. We
term this measure ‘‘relative structural diversity’’ (divrel).
divrel~
ncluster
ntotal
Higher values for divrel indicate higher structural diversity. The
values for divrel can vary from just above zero (when there is only
one cluster) to 1 (when each compound defines a separate cluster).
For our analysis, we have used the structural TGT keys [116,117]
consisting of 2D pharmacophore features with atom types and
distances.
Violation of Lipinski’s Rule-of-Five
Lipinski’s Rule-of-Five [65] identifies compounds with proper-
ties that would likely make them an orally active drug in humans.
The set of four rules describes molecular properties important for a
drug’s pharmacokinetic properties in the human organism,
including its absorption, distribution, metabolism, excretion and
toxicity (ADME/Tox). Violation of Lipinski’s Rule-of-Five was
calculated by ACD10 logD Suite. Violation was assumed when
there was a contradiction to any of the four rules.
Data on passive diffusion across the blood-brain barrier
The most common value describing permeability across the
blood-brain barrier (BBB) is the logBB. It is defined as the
logarithmic ratio between the concentration of a compound in
brain and blood. LogBB values below zero indicate poor
penetration of the BBB. LogBB values were compiled from a
number of published papers [58,118–128].
Distribution of FIASMAs across the therapeutic and
structural classes of the ATC system
The five-level ATC drug classification system [69,129,130] was
developed in the early 1970s and provides a comprehensive and
logical classification system for categorizing pharmaceutical
ingredients approved for medical use in humans. While the first
level indicates the main anatomical target of the compound, the
second level codes for the pharmacologically-relevant therapeutic
main group. The third level indicates the pharmacological
subgroup and the fourth the chemical subgroup. The fifth level
represents the chemical substance, namely the actual drug entity.
On the first level, the code comprises 14 anatomical regions
ranging from A (Alimentary tract and metabolism) to V (Various).
On the second level, the code consists of 86 pharmacologically-
relevant therapeutic groups. Molecular structures of the drugs in
their corresponding free base/acid forms were obtained from the
SuperDrug database [131]. Export was performed in May 2007,
based on the 2005 version of the ATC system. Since we analyzed
molecular descriptors of defined molecules, our approach
excluded drugs which are entire plants, extracts, drug mixtures,
colloids, biopolymers, resins, large peptides and inorganic
substances like metals and simple salts. Furthermore, we excluded
compounds with a quaternary nitrogen atom, as they do not cross
biological membranes via passive diffusion [56]. All compounds
were analyzed by their appearance in the ATC system, i.e.
substances with multiple effects and different therapeutic indica-
tions or different enantiomeric forms were found more than once
within the system. In order to determine the distribution of drugs
across the ATC system, we used the second level of the 2005
version. Uneven distribution of FIASMAs was tested by a
contingency table and one-sided Fisher test. Within this contin-
gency table, the multiple test correction (Benjamini-Hochberg
[90]) identified therapeutic groups with a significantly enriched
fraction of FIASMAs [132].
Distribution of FIASMAs across natural products
Molecular structures of ‘‘Pure Natural Products’’ were down-
loaded from MicroSourceDiscovery [66] and analysed using the
random forest model based on the whole experimental set. This set
of ‘‘Pure Natural Products’’ consisted of 800 alkaloids, flavonoids,
sterols/triterpenes, diterpenes/sesquiterpenes, benophenones/
chalcones/stilbenes, limonoids/quassinoids and chomones/cour-
marines, benzofurans/benzopyrans, rotenoids/xanthones, carbo-
hydrates and benztropolones/depsides/depsidones. Compounds
with a quaternary nitrogen atom and duplicates were again
excluded from this analysis.
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